- About Us
-
Medicines under development
- SB-REG-KMAS – stem cells in the treatment of mastitis in cows
- SB-REG-CORTO – innovative cell therapy for osteoarthritis in dogs
- SB-REG-HORTO – stem cell therapy for horses
- SB-REG-CSKIN – cell therapy for dogs and cats with atopic dermatitis
- SB-REG-FKIDNEY – cell therapy for kidneys
- SB-REG-CDM – stem cell therapy in canine neurology
- SB-REG-HMILA – ILA-1 biological therapy for horses and dogs
- Therapies
- Treatment of animals
- Our R&D
- Contact
- Home
- > R&D: mesenchymal stem cells in humans
Mesenchymal cells in humans
The potential of MSCs in human medicine
Mesenchymal stem cells (MSCs) are a population of cells capable of differentiating into connective tissues such as cartilage, bone, or adipose tissue.
They have been used in veterinary medicine for years – in the treatment of orthopaedic injuries, inflammation and skin diseases (Aleksiewicz et al., 2013). Currently, more and more research is focusing on their potential in human therapy.
Preclinical and translational research
In numerous research projects, MSCs and progenitor cells with specific properties (e.g., glial progenitors) are being tested in large and small animal models.
Examples include:
- glial cell transplants using modern hydrogel carriers and conducted under MRI guidance (Malysz-Cymborska et al., 2018),
- research on the intra-arterial administration of MSCs as a minimally invasive treatment strategy for generalised neurodegeneration (Malysz-Cymborska et al., 2021),
- tests of multi-site administration of progenitors to improve myelination and prolong survival in demyelinating diseases (Rogujski et al., 2024; Stanaszek et al., 2021)
The results of these studies indicate the significant potential of MSCs and related cells in the treatment of neurodegenerative diseases, including multiple sclerosis and diseases involving myelin damage.
Preclinical and translational research
In numerous research projects, MSCs and progenitor cells with specific properties (e.g., glial progenitors) are being tested in large and small animal models.
Examples include:
- glial cell transplants using modern hydrogel carriers and conducted under MRI guidance (Malysz-Cymborska et al., 2018),
- research on the intra-arterial administration of MSCs as a minimally invasive treatment strategy for generalised neurodegeneration (Malysz-Cymborska et al., 2021),
- tests of multi-site administration of progenitors to improve myelination and prolong survival in demyelinating diseases (Rogujski et al., 2024; Stanaszek et al., 2021)
The results of these studies indicate the significant potential of MSCs and related cells in the treatment of neurodegenerative diseases, including multiple sclerosis and diseases involving myelin damage.
ImmuImmunology and safety
From the perspective of clinical implementation, the immunological properties of MSCs and glial progenitors are crucial.
Studies have shown that these cells have immunomodulatory capabilities, which reduces the risk of rejection and allows them to be used in allogeneic therapy (Klimczak et al., 2019).
PRP and connection with MSC
An important area of research is combining MSCs with platelet-rich plasma (PRP). PRP, as a source of natural growth factors, supports bone healing and regeneration processes (Skwarcz et al., 2019a; Skwarcz et al., 2019b). The combination of MSCs and PRP may become the standard treatment for orthopaedic injuries and chronic inflammation in humans in the future.
The future of regenerative therapies
The results of research to date confirm that MSC and PRP are a viable alternative to symptomatic therapies.
Work is underway to develop drugs and clinical procedures that will enable their wider use in neurology, orthopaedics and human regenerative medicine.
These implementations are based on experience gained in veterinary medicine (Sanford Biotech) and translational research conducted in collaboration with academic centres.